BRPI0812835A2 - Combinações antitumorais contendo um agente inibidor de vegf e do irinotecano - Google Patents

Combinações antitumorais contendo um agente inibidor de vegf e do irinotecano

Info

Publication number: BRPI0812835A2
Authority: BR; Brazil
Prior art keywords: irinotecan; vegf; combinations containing; inhibitor agent; tumor
Prior art date: 2007-07-05

Application number

BRPI0812835-9A2A

Other languages

English (en)

Inventor

Marie-Christine Bissery

Marielle Chiron-Blondel

Pascale Lejeune

Patricia Vrignaud

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-05

Filing date

2008-07-02

Publication date

2014-12-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38961256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0812835(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-07-02 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2014-12-09 Publication of BRPI0812835A2 publication Critical patent/BRPI0812835A2/pt

2020-09-08 Publication of BRPI0812835B1 publication Critical patent/BRPI0812835B1/pt

2021-05-25 Publication of BRPI0812835B8 publication Critical patent/BRPI0812835B8/pt

Links

102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title 1
230000000259 anti-tumor effect Effects 0.000 title 1
239000003795 chemical substances by application Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title 1
229960004768 irinotecan Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

BRPI0812835A 2007-07-05 2008-07-02 combinações e produtos contendo um agente inibidor de vegf e do irinotecano. BRPI0812835B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR0704868A FR2918279B1 (fr)	2007-07-05	2007-07-05	Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
FR0704868		2007-07-05
PCT/FR2008/000943 WO2009024667A2 (fr)	2007-07-05	2008-07-02	Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan

Publications (3)

Publication Number	Publication Date
BRPI0812835A2 true BRPI0812835A2 (pt)	2014-12-09
BRPI0812835B1 BRPI0812835B1 (pt)	2020-09-08
BRPI0812835B8 BRPI0812835B8 (pt)	2021-05-25

Family

ID=38961256

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0812835A BRPI0812835B8 (pt)	2007-07-05	2008-07-02	combinações e produtos contendo um agente inibidor de vegf e do irinotecano.

Country Status (24)

Country	Link
US (3)	US20100160233A1 (pt)
EP (1)	EP2173349B1 (pt)
JP (4)	JP2010532335A (pt)
KR (4)	KR20180105261A (pt)
CN (3)	CN105833244A (pt)
AR (1)	AR067420A1 (pt)
AT (1)	ATE500829T1 (pt)
AU (1)	AU2008290442B2 (pt)
BR (1)	BRPI0812835B8 (pt)
CA (1)	CA2693152C (pt)
CY (1)	CY1111675T1 (pt)
DE (1)	DE602008005457D1 (pt)
DK (1)	DK2173349T3 (pt)
ES (1)	ES2362637T3 (pt)
FR (1)	FR2918279B1 (pt)
HR (1)	HRP20110432T1 (pt)
IL (2)	IL203132A (pt)
MX (1)	MX2009013950A (pt)
PL (1)	PL2173349T3 (pt)
PT (1)	PT2173349E (pt)
RS (1)	RS51777B (pt)
RU (1)	RU2471483C2 (pt)
SI (1)	SI2173349T1 (pt)
WO (1)	WO2009024667A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2377318T3 (es)	2002-09-06	2012-03-26	Cerulean Pharma Inc.	Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
US20080176958A1 (en)	2007-01-24	2008-07-24	Insert Therapeutics, Inc.	Cyclodextrin-based polymers for therapeutics delivery
ES2704986T3 (es) *	2008-10-16	2019-03-21	Celator Pharmaceuticals Inc	Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
ES2354922B1 (es)	2009-09-02	2012-02-07	Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron	Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
US20130029909A1 (en) *	2009-09-15	2013-01-31	John Ryan	Treatment of cancer
KR20190049934A (ko)	2011-01-13	2019-05-09	리제너론 파아마슈티컬스, 인크.	혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) *	2011-04-26	2018-09-16	Sanofi Sa	تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US20140094432A1 (en)	2012-10-02	2014-04-03	Cerulean Pharma Inc.	Methods and systems for polymer precipitation and generation of particles
EA035674B1 (ru)	2014-07-18	2020-07-24	Санофи	Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
HUE059827T2 (hu)	2017-11-30	2023-01-28	Regeneron Pharma	VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101433715B (zh) *	1999-06-08	2013-04-17	里珍纳龙药品有限公司	具有改善的药物动力学特性的修饰嵌合多肽
JP2005525367A (ja) *	2002-03-01	2005-08-25	フアルマシア・イタリア・エツセ・ピー・アー	塩酸イリノテカンの結晶多形
AR046510A1 (es) *	2003-07-25	2005-12-14	Regeneron Pharma	Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005016369A1 (en) *	2003-08-06	2005-02-24	Regeneron Pharmaceuticals, Inc.	Use of a vegf antagonist in combination with radiation therapy
MXPA06014689A (es) *	2004-06-18	2008-03-11	Regeneron Pharma	Inhibidores del vegf para el tratamiento de efusion pleural maligna.
FR2878749B1 (fr) *	2004-12-03	2007-12-21	Aventis Pharma Sa	Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives

2007
- 2007-07-05 FR FR0704868A patent/FR2918279B1/fr active Active
2008
- 2008-07-02 PT PT08827826T patent/PT2173349E/pt unknown
- 2008-07-02 RU RU2010103781/15A patent/RU2471483C2/ru active Protection Beyond IP Right Term
- 2008-07-02 CN CN201610141168.3A patent/CN105833244A/zh active Pending
- 2008-07-02 KR KR1020187026491A patent/KR20180105261A/ko not_active Ceased
- 2008-07-02 CN CN201310556556.4A patent/CN103623392A/zh active Pending
- 2008-07-02 MX MX2009013950A patent/MX2009013950A/es active IP Right Grant
- 2008-07-02 CN CN200880023537A patent/CN101686975A/zh active Pending
- 2008-07-02 KR KR1020167017056A patent/KR20160079918A/ko not_active Ceased
- 2008-07-02 SI SI200830256T patent/SI2173349T1/sl unknown
- 2008-07-02 RS RS20110215A patent/RS51777B/sr unknown
- 2008-07-02 KR KR1020107000011A patent/KR20100031123A/ko not_active Ceased
- 2008-07-02 JP JP2010514042A patent/JP2010532335A/ja active Pending
- 2008-07-02 DK DK08827826.2T patent/DK2173349T3/da active
- 2008-07-02 KR KR1020157010064A patent/KR20150048910A/ko not_active Ceased
- 2008-07-02 EP EP08827826A patent/EP2173349B1/fr active Active
- 2008-07-02 AT AT08827826T patent/ATE500829T1/de active
- 2008-07-02 AU AU2008290442A patent/AU2008290442B2/en active Active
- 2008-07-02 BR BRPI0812835A patent/BRPI0812835B8/pt active IP Right Grant
- 2008-07-02 HR HR20110432T patent/HRP20110432T1/hr unknown
- 2008-07-02 ES ES08827826T patent/ES2362637T3/es active Active
- 2008-07-02 WO PCT/FR2008/000943 patent/WO2009024667A2/fr not_active Ceased
- 2008-07-02 PL PL08827826T patent/PL2173349T3/pl unknown
- 2008-07-02 CA CA2693152A patent/CA2693152C/fr not_active Expired - Fee Related
- 2008-07-02 DE DE602008005457T patent/DE602008005457D1/de active Active
- 2008-07-04 AR ARP080102894A patent/AR067420A1/es not_active Application Discontinuation
2010
- 2010-01-04 US US12/651,767 patent/US20100160233A1/en not_active Abandoned
- 2010-01-04 IL IL203132A patent/IL203132A/en active IP Right Grant
2011
- 2011-06-08 CY CY20111100551T patent/CY1111675T1/el unknown
2014
- 2014-01-13 US US14/153,795 patent/US20140127202A1/en not_active Abandoned
- 2014-08-29 JP JP2014174963A patent/JP2014240422A/ja active Pending
2015
- 2015-08-31 IL IL240965A patent/IL240965A0/en unknown
2016
- 2016-11-16 JP JP2016222826A patent/JP2017052789A/ja active Pending
2018
- 2018-08-15 JP JP2018152805A patent/JP2019006785A/ja active Pending
2019
- 2019-02-11 US US16/272,315 patent/US20190275147A1/en not_active Abandoned

Also Published As

Publication number	Publication date
FR2918279A1 (fr)	2009-01-09
CA2693152A1 (fr)	2009-02-26
HRP20110432T1 (hr)	2011-07-31
BRPI0812835B8 (pt)	2021-05-25
JP2010532335A (ja)	2010-10-07
DK2173349T3 (da)	2011-06-27
AU2008290442A1 (en)	2009-02-26
RU2471483C2 (ru)	2013-01-10
PL2173349T3 (pl)	2011-08-31
US20100160233A1 (en)	2010-06-24
PT2173349E (pt)	2011-06-02
WO2009024667A2 (fr)	2009-02-26
CA2693152C (fr)	2019-02-26
RS51777B (sr)	2011-12-31
CN105833244A (zh)	2016-08-10
CY1111675T1 (el)	2015-10-07
WO2009024667A3 (fr)	2009-04-23
JP2017052789A (ja)	2017-03-16
MX2009013950A (es)	2010-03-09
KR20160079918A (ko)	2016-07-06
CN101686975A (zh)	2010-03-31
CN103623392A (zh)	2014-03-12
US20140127202A1 (en)	2014-05-08
JP2019006785A (ja)	2019-01-17
KR20180105261A (ko)	2018-09-27
ATE500829T1 (de)	2011-03-15
IL240965A0 (en)	2015-10-29
KR20100031123A (ko)	2010-03-19
JP2014240422A (ja)	2014-12-25
EP2173349B1 (fr)	2011-03-09
IL203132A (en)	2015-09-24
BRPI0812835B1 (pt)	2020-09-08
DE602008005457D1 (de)	2011-04-21
EP2173349A2 (fr)	2010-04-14
SI2173349T1 (sl)	2011-06-30
AR067420A1 (es)	2009-10-07
AU2008290442B2 (en)	2013-06-27
US20190275147A1 (en)	2019-09-12
KR20150048910A (ko)	2015-05-07
RU2010103781A (ru)	2011-08-10
FR2918279B1 (fr)	2010-10-22
ES2362637T3 (es)	2011-07-08

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-28	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-11-19	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-03-31	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-07-21	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-09-08	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-05-14	B25D	Requested change of name of applicant approved	Owner name: AVENTIS PHARMA SARL (FR)
2024-05-28	B25G	Requested change of headquarter approved	Owner name: AVENTIS PHARMA SARL (FR)
2024-06-18	B25A	Requested transfer of rights approved	Owner name: SANOFI MATURE IP (FR)

Publication	Publication Date	Title
BRPI0812835A2 (pt)	2014-12-09	Combinações antitumorais contendo um agente inibidor de vegf e do irinotecano
BRPI0809978A2 (pt)	2014-10-07	Dispositivos e métodos de dispensação de gotículas
DK2107905T3 (da)	2011-01-31	Fast sammensætning omfattende alogliptin og pioglitazon
DK2077866T3 (da)	2012-11-26	Catheter gripping device
DK2692341T3 (da)	2015-06-22	Misbrugs-resistent lægemiddelformulering
EP2050881A4 (en)	2015-01-21	ARROW
EP2241332A4 (en)	2011-01-26	THERAPEUTIC AGENT AGAINST PRITURE
ES2614941T8 (es)	2017-06-16	Dispositivo de agente de revestimiento y dispositivo de revestimiento
DK2001556T3 (da)	2014-11-10	Thioninium-forbindelser og anvendelse deraf
EP2088865A4 (en)	2010-03-17	GUGGULPHOSPHOLIPID METHOD AND COMPOSITIONS
BRPI0715508A2 (pt)	2013-10-29	Dispositivos e métodos de plantio
BRPI0920681A2 (pt)	2015-12-29	inibidores de decahidro-1h-indenoquinolinona e decahidro-3h-ciclopentafenantridinona de cyp17
BRPI0814199A2 (pt)	2015-01-27	Dispositivo de manipulação de âncora
EP1986635A4 (en)	2009-04-22	ANTI CANCER AGENTS
EP2191283A4 (en)	2016-06-22	TEMPORAL DIMENSIONAL REFLECTOMETRY SYSTEM AND METHOD OF USE
DE112007001705A5 (de)	2009-10-15	Sicherungsvorrichtung
EP1993925A4 (en)	2012-03-14	DEVICES AND METHODS FOR VISIBILITY
FI20065246L (fi)	2007-10-21	Suojalaite
DK2089708T3 (da)	2012-12-03	Forudsigelige kræft-immunterapi parametre
TWM298784U (en)	2006-10-01	Attenuator
EP2105140A4 (en)	2010-01-27	CANCER AGENT
BRPI0810741A2 (pt)	2014-10-21	Dispositivo de jogo auto-implementável
DE502007000195D1 (de)	2008-12-11	Absicherungsvorrichtung
AT504095A3 (de)	2009-05-15	Halteeinrichtung
SE0600253L (sv)	2007-01-16	Hållaranordning